ReviewComputational and structural biotechnology journal2016
A Single-use Strategy to Enable Manufacturing of Affordable Biologics.
Review in Computational and structural biotechnology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Industrial Bioreactor Technologies for Modern Biomanufacturing: Recent Applications in Microbial, Mammalian, and Plant-Based Systems.Molecular biotechnology · 2026Review
- Review
- Metabolic Engineering of Terpenoid Biosynthesis in Medicinal Plants: From Genomic Insights to Biotechnological Applications.Current issues in molecular biology · 2025Review
- Purification of Monoclonal Antibodies Using Chromatographic Methods: Increasing Purity and Recovery.Advanced pharmaceutical bulletin · 2025Review
- Environmental Impacts of Cultured Meat: A Cradle-to-Gate Life Cycle Assessment.ACS food science & technology · 2025Article
- Gene Delivery From Granular Scaffolds for Tunable Biologics Manufacturing.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Review
- Killer to cure: Expression and production costs calculation of tobacco plant-made cancer-immune checkpoint inhibitors.Plant biotechnology journal · 2023Article
- On-demand biomanufacturing through synthetic biology approach.Materials today. Bio · 2023Article
- Advancing herbal medicine: enhancing product quality and safety through robust quality control practices.Frontiers in pharmacology · 2023Review
- Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies.International journal of molecular sciences · 2022Review
- Rapid monitoring of high-mannose glycans during cell culture process of therapeutic monoclonal antibodies using lectin affinity chromatography.Journal of separation science · 2022Article
- Exploring the limits of conventional small-scale CHO fed-batch for accelerated on demand monoclonal antibody production.Bioprocess and biosystems engineering · 2022Article
- Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP.Frontiers in bioengineering and biotechnology · 2022Article
- CDMOs Play a Critical Role in the Biopharmaceutical Ecosystem.Frontiers in bioengineering and biotechnology · 2022Review
- Interference chromatography: a novel approach to optimizing chromatographic selectivity and separation performance for virus purification.BMC biotechnology · 2020Article
- Multimeric fusion single-chain variable fragments as potential novel high-capacity ligands.FEBS open bio · 2020Article
- Versatile biomanufacturing through stimulus-responsive cell-material feedback.Nature chemical biology · 2019Article
- Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development.Frontiers in bioengineering and biotechnology · 2019Review
- Economic Analysis of Batch and Continuous Biopharmaceutical Antibody Production: A Review.Journal of pharmaceutical innovation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current processing paradigm of large manufacturing facilities dedicated to single product production is no longer an effective approach for best manufacturing practices. Increasing competition for new indications and the launch of biosimilars for the monoclonal antibody market have put pressure on manufacturers to produce at lower cost. Single-use technologies and continuous upstream processes have proven to be cost-efficient options to increase biomass production but as of today the adoption has been only minimal for the purification operations, partly due to concerns related to cost and scale-up. This review summarizes how a single-use holistic process and facility strategy can overcome scale limitations and enable cost-efficient manufacturing to support the growing demand for affordable biologics. Technologies enabling high productivity, right-sized, small footprint, continuous, and automated upstream and downstream operations are evaluated in order to propose a concept for the flexible facility of the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.